AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33001564 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental floss with soft ellipsoidal knots (no floss users)
Number of subjects: 33
Study 33001564 — intervention group
Group type: COMPARATOR
Intervention: Conventional dental floss (no floss users)
Number of subjects: 33
Study 35235573 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard SST arm
Number of subjects: 451
Study 35235573 — intervention group
Group type: EXPERIMENTAL
Intervention: Lottery incentivized SST arm
Number of subjects: 451
Study 35235573 — intervention group
Group type: COMPARATOR
Intervention: Standard of care arm
Number of subjects: 451
Study 35235573 — intervention group
Group type: COMPARATOR
Intervention: Standard SST arm vs Standard of care arm
Number of subjects: 451
Study 35235573 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost per person tested for Standard SST
Number of subjects: 451
Study 35235573 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost per person tested for Lottery incentivized SST
Number of subjects: 451
Study 35235573 — intervention group
Group type: COMPARATOR
Intervention: Cost per person tested for Standard of care
Number of subjects: 451
Study 32819908 — intervention group
Group type: EXPERIMENTAL
Intervention: Marfan syndrome and Loeys-Dietz syndrome
Number of subjects: 68
Study 32819908 — intervention group
Group type: EXPERIMENTAL
Intervention: Tortuosity index of the vertebrobasilar system
Number of subjects: 68
Study 32819908 — intervention group
Group type: COMPARATOR
Intervention: Controls (patients with headache)
Number of subjects: 68
Study 34665890 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral THC 7.5 mg
Number of subjects: 0
Study 34665890 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral THC 15 mg
Number of subjects: 0
Study 34665890 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34003796 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutralizing antibodies (NAbs) induced by WT DENV1 or DENV3 infections
Number of subjects: 0
Study 34003796 — intervention group
Group type: COMPARATOR
Intervention: Neutralizing antibodies (NAbs) induced by Dengvaxia
Number of subjects: 0
Study 34903493 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine injection and oral citalopram
Number of subjects: 150
Study 34903493 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine injection and oral placebo
Number of subjects: 150
Study 34903493 — intervention group
Group type: COMPARATOR
Intervention: Injective and oral placebo
Number of subjects: 150
Study 33690962 — intervention group
Group type: EXPERIMENTAL
Intervention: Fusion of original image and three discriminative region images
Number of subjects: 479
Study 33063461 — intervention group
Group type: EXPERIMENTAL
Intervention: Low level laser therapy (LLLT) using 980 nm diode laser at 0.1 W output power, energy density of 4 J/cm2 delivered at six sites for 10 seconds each
Number of subjects: 20
Study 33063461 — intervention group
Group type: COMPARATOR
Intervention: No adjunctive treatment (Control Group)
Number of subjects: 20
Study 35166103 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovenous laser ablation (EVLA) 1470‐nm with Tulip‐TipTM fiber
Number of subjects: 280
Study 35166103 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency ablation (RFA) ClosureFastTM
Number of subjects: 280
Study 33358401 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab
Number of subjects: 116
Study 33358401 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab (PD-L1 positive subgroup)
Number of subjects: 116
Study 33358401 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 116
Study 33277296 — intervention group
Group type: EXPERIMENTAL
Intervention: IPV prevention interventions for the general population
Number of subjects: 0
Study 35031587 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg simvastatin
Number of subjects: 140
Study 35031587 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 34016004 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheumatoid arthritis group at 06:00 and 22:00 h
Number of subjects: 30
Study 34016004 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheumatoid arthritis group at 22:00 h
Number of subjects: 30
Study 34016004 — intervention group
Group type: COMPARATOR
Intervention: Control group at 06:00 h
Number of subjects: 30
Study 34016004 — intervention group
Group type: COMPARATOR
Intervention: Control group at 06:00 and 22:00 h
Number of subjects: 30
Study 34016004 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheumatoid arthritis group
Number of subjects: 30
Study 33128912 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (1 g intravenous over 10 min followed by 1 g over 8 h)
Number of subjects: 100
Study 33128912 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 33128912 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 100
Study 34726958 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib (250 mg once daily for 24 months)
Number of subjects: 234
Study 34726958 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin (80 mg/m2 on day 1) plus Vinorelbine (25 mg/m2 on days 1 and 8; cis/vin) once every 3 weeks for four cycles
Number of subjects: 234
Study 34726958 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib
Number of subjects: 234
Study 34726958 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin plus Vinorelbine
Number of subjects: 234
Study 33743284 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Number of subjects: 20
Study 33743284 — intervention group
Group type: COMPARATOR
Intervention: Non-ketogenic diet
Number of subjects: 20
Study 32891163 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) 4 IU/d on day 2 of the previous menstrual cycle until the trigger day
Number of subjects: 105
Study 32891163 — intervention group
Group type: COMPARATOR
Intervention: No pretreatment (Control group)
Number of subjects: 105
Study 35089613 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine (MZ) 15–45 mg/day
Number of subjects: 80
Study 35089613 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (ST) 25–200 mg/day
Number of subjects: 80
Study 33577899 — intervention group
Group type: EXPERIMENTAL
Intervention: AirSeal Insufflation (AIS) at 12 mm Hg
Number of subjects: 202
Study 33577899 — intervention group
Group type: EXPERIMENTAL
Intervention: AirSeal Insufflation (AIS) at 15 mm Hg
Number of subjects: 202
Study 33577899 — intervention group
Group type: COMPARATOR
Intervention: Conventional Insufflation (CIS) at 15 mm Hg
Number of subjects: 202
Study 32536683 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐aenial immersed in coffee
Number of subjects: 90
Study 32536683 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐aenial immersed in tomato sauce
Number of subjects: 90
Study 32536683 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonize immersed in coffee
Number of subjects: 90
Study 32536683 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonize immersed in tomato sauce
Number of subjects: 90
Study 32536683 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtek™ Z250
Number of subjects: 90
Study 32536683 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐aenial after polishing
Number of subjects: 90
Study 32536683 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtek™ Z250 after polishing
Number of subjects: 90
Study 32536683 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonize after polishing
Number of subjects: 90
Study 34924318 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise training
Number of subjects: 90
Study 34924318 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile app
Number of subjects: 90
Study 34924318 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable smartwatch
Number of subjects: 90
Study 34924318 — intervention group
Group type: COMPARATOR
Intervention: Technology groups combined (mobile app and smartwatch)
Number of subjects: 90
Study 34924318 — intervention group
Group type: COMPARATOR
Intervention: Secondary outcomes (Six Minute Walk Test, exercise behaviour, muscle function, physical capacity)
Number of subjects: 90
Study 34887918 — intervention group
Group type: EXPERIMENTAL
Intervention: Microneedling plus topical pimecrolimus 1%
Number of subjects: 15
Study 34887918 — intervention group
Group type: COMPARATOR
Intervention: Topical pimecrolimus 1%
Number of subjects: 15
Study 32675791 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice from inexperienced male physician
Number of subjects: 283
Study 32675791 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice from inexperienced female physician
Number of subjects: 283
Study 32675791 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice from experienced male physician
Number of subjects: 283
Study 32675791 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice from experienced female physician
Number of subjects: 283
Study 36029192 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine + Oxybutynin
Number of subjects: 10
Study 36029192 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 33857681 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes LIVE© (virtual environment)
Number of subjects: 0
Study 33857681 — intervention group
Group type: COMPARATOR
Intervention: Traditional website format
Number of subjects: 0
Study 33358239 — intervention group
Group type: EXPERIMENTAL
Intervention: CPC + Zn + F mouthrinse
Number of subjects: 120
Study 33358239 — intervention group
Group type: COMPARATOR
Intervention: EO mouthrinse
Number of subjects: 120
Study 33358239 — intervention group
Group type: COMPARATOR
Intervention: Control (toothbrushing with standard fluoride toothpaste and manual toothbrush)
Number of subjects: 120
Study 32557211 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 23
Study 32557211 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 23
Study 32557211 — intervention group
Group type: EXPERIMENTAL
Intervention: MBSR
Number of subjects: 23
Study 36314374 — intervention group
Group type: EXPERIMENTAL
Intervention: Responsive parenting intervention delivered via Integrated Behavioral Health (IBH)
Number of subjects: 65
Study 36314374 — intervention group
Group type: COMPARATOR
Intervention: IBH attention control focused on promoting healthy mental health
Number of subjects: 65
Study 33410388 — intervention group
Group type: EXPERIMENTAL
Intervention: MFES gait training (experimental group)
Number of subjects: 40
Study 33410388 — intervention group
Group type: COMPARATOR
Intervention: Conventional gait training (control group)
Number of subjects: 40
Study 32969580 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 574
Study 32969580 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 574
Study 32557238 — intervention group
Group type: EXPERIMENTAL
Intervention: CCTA-based radiomics machine learning nomogram
Number of subjects: 154
Study 33674858 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive framing warning (e.g., '7 out of 10 people will not experience nausea')
Number of subjects: 99
Study 33674858 — intervention group
Group type: COMPARATOR
Intervention: Negative framing warning (e.g., '3 out of 10 people will experience nausea')
Number of subjects: 99
Study 33674858 — intervention group
Group type: COMPARATOR
Intervention: General warning (e.g., 'a proportion of people will experience nausea')
Number of subjects: 99
Study 33674858 — intervention group
Group type: COMPARATOR
Intervention: No warning
Number of subjects: 99
Study 36267499 — intervention group
Group type: EXPERIMENTAL
Intervention: SOC+pegfilgrastim (0.6 mg subcutaneously on Day 1 and Day 8)
Number of subjects: 34
Study 36267499 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC) with prednisolone
Number of subjects: 34
Study 36267499 — intervention group
Group type: EXPERIMENTAL
Intervention: SOC+pegfilgrastim
Number of subjects: 34
Study 36267499 — intervention group
Group type: COMPARATOR
Intervention: SOC
Number of subjects: 34
Study 33428221 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric prilocaine (60 mg intrathecal)
Number of subjects: 50
Study 33428221 — intervention group
Group type: COMPARATOR
Intervention: Hyperbaric bupivacaine (12.5 mg intrathecal)
Number of subjects: 50
Study 33428221 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (prilocaine and bupivacaine)
Number of subjects: 50
Study 35654766 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplement
Number of subjects: 47
Study 35654766 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 36226998 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous neuromodulation (TN)
Number of subjects: 57
Study 36226998 — intervention group
Group type: EXPERIMENTAL
Intervention: Double acupoint combination therapy (TN PC6 combined with ST36)
Number of subjects: 57
Study 34190954 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated extraction (Loccus, Extracta Kit FAST)
Number of subjects: 300
Study 34190954 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual extraction (BioGene Kit, Bioclin, Quibasa)
Number of subjects: 300
Study 34190954 — intervention group
Group type: EXPERIMENTAL
Intervention: Quick extraction methods (Lucigen, Quick DNA Extract Kit)
Number of subjects: 300
Study 32304300 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 0
Study 32304300 — intervention group
Group type: COMPARATOR
Intervention: Mefenamic acid
Number of subjects: 0
Study 35768818 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth programme for sitting less and moving more at work (13 weeks duration)
Number of subjects: 220
Study 35768818 — intervention group
Group type: COMPARATOR
Intervention: Usual healthcare and information on health benefits of sitting less and moving more (control group)
Number of subjects: 220
Study 34504446 — intervention group
Group type: EXPERIMENTAL
Intervention: Arbaclofen
Number of subjects: 130
Study 34504446 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 36145254 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (cocktail of six probiotic strains from Bifidobacterium and Lactobacillus) for 12 weeks
Number of subjects: 132
Study 36145254 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 132
Study 36145254 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical sachet devoid of living microorganisms)
Number of subjects: 132
Study 34546300 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral L rhamnosus GG (1 × 10^10 colony-forming units) twice daily in the ICU (n = 1321)
Number of subjects: 2653
Study 34546300 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 1332)
Number of subjects: 2653
Study 34546300 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral L rhamnosus GG
Number of subjects: 2653
Study 34546300 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2653
Study 37191887 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 weeks plaster cast immobilisation
Number of subjects: 80
Study 37191887 — intervention group
Group type: COMPARATOR
Intervention: 6 weeks plaster cast immobilisation
Number of subjects: 80
Study 33656262 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute Kidney Injury (AKI) cases
Number of subjects: 314
Study 33656262 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert panel assessment of AKI preventability
Number of subjects: 314
Study 35693457 — intervention group
Group type: EXPERIMENTAL
Intervention: Sectioning of the ACL and posterolateral structures (ACL-first group)
Number of subjects: 14
Study 35693457 — intervention group
Group type: EXPERIMENTAL
Intervention: Sectioning of the FCL, PLT, PFL, and ACL (FCL-first group)
Number of subjects: 14
Study 35693457 — intervention group
Group type: EXPERIMENTAL
Intervention: Sectioning of the ACL
Number of subjects: 14
Study 35693457 — intervention group
Group type: EXPERIMENTAL
Intervention: Sectioning of the FCL
Number of subjects: 14
Study 35693457 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ACL and FCL sectioned
Number of subjects: 14
Study 35693457 — intervention group
Group type: COMPARATOR
Intervention: Comparison of sectioning sequence (ACL first vs FCL first)
Number of subjects: 14
Study 33262281 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast Track (FT) intervention
Number of subjects: 0
Study 35848844 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional rehabilitation associated with abdominal electrical stimulation (EE) via 8‐ and 20‐Hz Functional Electrical Stimulation (FES) of the abdominal muscles for 30 minutes daily for two weeks
Number of subjects: 10
Study 35848844 — intervention group
Group type: COMPARATOR
Intervention: Conventional intestinal rehabilitation
Number of subjects: 10
Study 32270527 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual supply (Rural/Individual)
Number of subjects: 1110
Study 32270527 — intervention group
Group type: COMPARATOR
Intervention: Rural/Public
Number of subjects: 1110
Study 32270527 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing bacterial load in drinking water
Number of subjects: 1110
Study 32270527 — intervention group
Group type: COMPARATOR
Intervention: Urban/Public
Number of subjects: 1110
Study 34241685 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron
Number of subjects: 90
Study 34241685 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 90
Study 34781770 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable resistance (WR) on lower legs during warm-up (200 g to 600 g)
Number of subjects: 28
Study 34781770 — intervention group
Group type: COMPARATOR
Intervention: Control group (unloaded)
Number of subjects: 28
Study 33755728 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued subcutaneous semaglutide 2.4 mg once weekly
Number of subjects: 803
Study 33755728 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 803
Study 32897034 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of brensocatib
Number of subjects: 256
Study 32897034 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg of brensocatib
Number of subjects: 256
Study 32897034 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 256
Study 32897034 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg and 25 mg of brensocatib
Number of subjects: 256
Study 35994841 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 140
Study 35994841 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 140
Study 35994841 — intervention group
Group type: COMPARATOR
Intervention: Usual care (telephone counselling)
Number of subjects: 140
Study 33497364 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated influenza vaccine (LAIV)
Number of subjects: 0
Study 33497364 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetravalent‐inactivated influenza vaccine (TIV)
Number of subjects: 0
Study 33497364 — intervention group
Group type: COMPARATOR
Intervention: LAIV
Number of subjects: 0
Study 32650750 — intervention group
Group type: EXPERIMENTAL
Intervention: 3DPPS Ti‐6AL‐4 V plates (Group B)
Number of subjects: 50
Study 32650750 — intervention group
Group type: COMPARATOR
Intervention: Conventional method of shaping reconstruction plates (Group A)
Number of subjects: 50
Study 36414827 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib (ER)
Number of subjects: 536
Study 36414827 — intervention group
Group type: COMPARATOR
Intervention: Gefitinib (GE)
Number of subjects: 536
Study 36414827 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib (ER) in exon 19 mutation patients
Number of subjects: 536
Study 36414827 — intervention group
Group type: COMPARATOR
Intervention: Gefitinib (GE) in exon 19 mutation patients
Number of subjects: 536
Study 36414827 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib (ER) in L858 mutation patients
Number of subjects: 536
Study 36414827 — intervention group
Group type: COMPARATOR
Intervention: Gefitinib (GE) in L858 mutation patients
Number of subjects: 536
Study 36414827 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib (ER) in patients with brain metastasis
Number of subjects: 536
Study 36414827 — intervention group
Group type: COMPARATOR
Intervention: Gefitinib (GE) in patients with brain metastasis
Number of subjects: 536
Study 32727225 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma tocopherol-enriched supplement
Number of subjects: 0
Study 32727225 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study 35940829 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (80 mg daily)
Number of subjects: 379
Study 35940829 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 379
Study 33797952 — intervention group
Group type: EXPERIMENTAL
Intervention: Bridge app
Number of subjects: 200
Study 33797952 — intervention group
Group type: COMPARATOR
Intervention: Financial assistance educational websites
Number of subjects: 200
Study 32430167 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamification
Number of subjects: 19
Study 32430167 — intervention group
Group type: COMPARATOR
Intervention: Conventional physiotherapy
Number of subjects: 19
Study 34747042 — intervention group
Group type: EXPERIMENTAL
Intervention: Accommodative support (AS) lenses
Number of subjects: 0
Study 34747042 — intervention group
Group type: COMPARATOR
Intervention: Control single vision (SV) lenses
Number of subjects: 0
Study 35691538 — intervention group
Group type: EXPERIMENTAL
Intervention: ClotTriever thrombectomy system
Number of subjects: 96
Study 32666927 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with lesions in both sexually-sensitive and visible areas
Number of subjects: 2009
Study 32666927 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased disease severity, lesions in both sexually-sensitive/visible or only visible areas
Number of subjects: 2009
Study 34922298 — intervention group
Group type: EXPERIMENTAL
Intervention: Varlitinib plus capecitabine
Number of subjects: 127
Study 34922298 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine alone
Number of subjects: 127
Study 34111412 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterolane-piperaquine-mefloquine
Number of subjects: 217
Study 34111412 — intervention group
Group type: COMPARATOR
Intervention: Artemether-lumefantrine
Number of subjects: 217
Study 34111412 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterolane-piperaquine
Number of subjects: 217
Study 33690909 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo 'anaesthetic' cream
Number of subjects: 60